We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.07 | -0.07% | 97.27 | 97.91 | 97.07 | 97.75 | 1,045,674 | 01:00:00 |
From May 2021 to May 2024
By Cristina Roca
Novartis AG said Thursday that it will use the proceeds from the recent sale of its stake in Roche Holding AG to buy back up to $15 billion of its shares by the end of 2023.
The Swiss pharmaceutical company said it is confident in its growth prospects. Its pipeline has up to 20 assets with significant sales potential, and sales are expected to increase at a compound annual growth rate of 4% or more through 2026, the company said.
Novartis in November agreed to sell its stake in Roche back to its rival for $20.7 billion.
The proceeds allow it to return value to shareholders without compromising its ability to engage in mergers and acquisitions, it said.
Write to Cristina Roca at cristina.roca@wsj.com
(END) Dow Jones Newswires
December 16, 2021 01:35 ET (06:35 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
